Audited Financial Results for the quarter and year ended 31 March, 2026

Results View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+15.4%Reaction day

₹220.50

prior close

₹236.23

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%+14.7% vs market

Pharmaceuticals peers, median of 165sector+0.1%+15.3% vs sector

On the reaction day the stock moved 14.7 pts more than Nifty Microcap 250 and 15.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.1

10m

+4.1

15m

+5.7

30m

+5.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+15.4+0.7+14.7+0.1+15.3

Next day

+12.7+0.7+12.1-0.1+12.9

+11.5+0.0+11.4-0.4+11.8

+9.8-1.1+10.8-1.4+11.1

+9.8+0.0+9.7-1.3+11.0

+10.2+0.3+9.9-1.7+11.8

+5.9+1.1+4.8-0.6+6.5

15d

+15.6+4.9+10.8-0.5+16.1

+19.8+5.3+14.5+2.6+17.2

+19.8+6.9+12.9+4.0+15.8

+50.0+11.9+38.1+7.1+42.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma reported consolidated revenue of Rs 29,509 million for FY2026, up 12.5% from Rs 26,228 million in FY2025. Profit after tax grew 9.8% to Rs 4,201 million from Rs 3,826 million. Diluted EPS improved to Rs 9.22 from Rs 8.40. The company declared an unmodified audit opinion from MSKA & Associates. The Board recommended a final dividend of Rs 0.90 per share (90%) for FY2025-26, subject to shareholder approval. The company expanded globally with two new wholly-owned subsidiaries formed in Ireland and Canada in January 2026.

Likely market impact

Strong double-digit revenue and profit growth with clean audit opinion and dividend declaration are positive signals for shareholders. The stock could see renewed interest given the consistent financial performance and global expansion.